image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 39.76
-4.81 %
$ 4.93 B
Market Cap
-12.37
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GH stock under the worst case scenario is HIDDEN Compared to the current market price of 39.8 USD, Guardant Health, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GH stock under the base case scenario is HIDDEN Compared to the current market price of 39.8 USD, Guardant Health, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one GH stock under the best case scenario is HIDDEN Compared to the current market price of 39.8 USD, Guardant Health, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GH

image
$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
739 M REVENUE
31.04%
-444 M OPERATING INCOME
21.45%
-436 M NET INCOME
8.98%
-240 M OPERATING CASH FLOW
26.19%
-261 M INVESTING CASH FLOW
-31.10%
-996 K FINANCING CASH FLOW
-0.21%
203 M REVENUE
0.82%
-111 M OPERATING INCOME
11.85%
-95.2 M NET INCOME
14.28%
-62.7 M OPERATING CASH FLOW
2.83%
303 M INVESTING CASH FLOW
2776.20%
-66.8 M FINANCING CASH FLOW
-2177.68%
Balance Sheet Guardant Health, Inc.
image
Current Assets 1.06 B
Cash & Short-Term Investments 840 M
Receivables 110 M
Other Current Assets 105 M
Non-Current Assets 430 M
Long-Term Investments 0
PP&E 279 M
Other Non-Current Assets 151 M
56.54 %7.42 %7.06 %18.79 %10.19 %Total Assets$1.5b
Current Liabilities 226 M
Accounts Payable 38.6 M
Short-Term Debt 0
Other Current Liabilities 187 M
Non-Current Liabilities 1.4 B
Long-Term Debt 1.14 B
Other Non-Current Liabilities 257 M
11.51 %70.30 %15.82 %Total Liabilities$1.6b
EFFICIENCY
Earnings Waterfall Guardant Health, Inc.
image
Revenue 739 M
Cost Of Revenue 290 M
Gross Profit 449 M
Operating Expenses 893 M
Operating Income -444 M
Other Expenses -7.22 M
Net Income -436 M
800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)(600m)(600m)739m(290m)449m(893m)(444m)7m(436m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.79% GROSS MARGIN
60.79%
-60.02% OPERATING MARGIN
-60.02%
-59.05% NET MARGIN
-59.05%
312.48% ROE
312.48%
-29.37% ROA
-29.37%
-35.31% ROIC
-35.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Guardant Health, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -436 M
Depreciation & Amortization 42.4 M
Capital Expenditures -35.1 M
Stock-Based Compensation 140 M
Change in Working Capital 0
Others 13.7 M
Free Cash Flow -275 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Guardant Health, Inc.
image
Wall Street analysts predict an average 1-year price target for GH of $40 , with forecasts ranging from a low of $30 to a high of $52 .
GH Lowest Price Target Wall Street Target
30 USD -24.55%
GH Average Price Target Wall Street Target
40 USD 0.60%
GH Highest Price Target Wall Street Target
52 USD 30.78%
Price
Max Price Target
Min Price Target
Average Price Target
55555050454540403535303025252020Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Guardant Health, Inc.
image
Sold
0-3 MONTHS
6.11 M USD 4
3-6 MONTHS
298 K USD 3
6-9 MONTHS
332 K USD 2
9-12 MONTHS
2.79 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Guardant Health: Tailwinds Are Beginning To Impact The Financials Guardant Health handily beat Q1 expectations and meaningfully increased full-year growth expectations. Guardant also continues to benefit from positive developments in relation to pricing, regulatory approval, reimbursement coverage, and study data. I expect Guardant's fundamentals to continue strengthening in coming quarters, which should lead its stock price higher. seekingalpha.com - 2 weeks ago
Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript Guardant Health, Inc. (NASDAQ:GH ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Tycho Peterson - Jefferies Bill Bonello - Craig-Hallum Subbu Nambi - Guggenheim Partners Puneet Souda - Leerink Partners Dan Leonard - UBS Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Luke Sergott - Barclays Operator Hello, everybody and welcome to the Guardant Health Q1 2025 Earnings Call. My name is Elliot, and I will be your coordinator today. seekingalpha.com - 2 weeks ago
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.46 per share a year ago. zacks.com - 2 weeks ago
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25%. businesswire.com - 2 weeks ago
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cancer detection (MCD) test demonstrated high specificity and clinically meaningful sensitivity across ten tumor types,* while also providing information to guide clinical diagnostic evaluation. The study was presented at the 2025 American Association for Cancer Research (AACR) annual meeting. Results of. businesswire.com - 2 weeks ago
CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Throughout release, "exome-wide" should read as "genome-wide". The updated release reads: GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer genome-wi. businesswire.com - 3 weeks ago
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer. Powered by the Guardant Infinity™ smart liquid biopsy platform, the advanced G. businesswire.com - 3 weeks ago
Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25-30 in Chicago. Key data that will be highlighted include: An oral presentation. businesswire.com - 3 weeks ago
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025 PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will. businesswire.com - 1 month ago
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant's portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinics in Canada. Bayshore HealthCare provides care to over 350,000 Canadians annually (excluding Quebec), and the agre. businesswire.com - 1 month ago
4 Healthcare Stocks With Massive Gains—and More to Come The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far. marketbeat.com - 1 month ago
8. Profile Summary

Guardant Health, Inc. GH

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 4.93 B
Dividend Yield 0.00%
Description Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Contact 505 Penobscot Drive, Redwood City, CA, 94063 https://guardanthealth.com
IPO Date Oct. 4, 2018
Employees 1999
Officers Dr. Helmy Eltoukhy Ph.D. Co-Founder, Co-Chief Executive Officer & Chairman Ms. Terilyn Juarez Monroe Chief People Officer Mr. Andy Ament Senior Vice President of Operations Mr. Kumud Kalia Chief Information Officer Ms. Gulshan Shaver J.D. Senior Vice President of Legal Affairs & Chief Compliance Officer Mr. John G. Saia J.D. Chief Legal Officer & Corporate Secretary Zarak Khurshid Vice President of Investor Relations Dr. AmirAli Talasaz Ph.D. Co-Chief Executive Officer & Director Ms. Darya Chudova Chief Technology Officer Mr. Michael Bell Chief Financial Officer